Lawrence Klein, Oruka Therapeutics CEO

Apogee, Spyre founder launch­es its third biotech and heads straight to Nas­daq

Af­ter cre­at­ing an­ti­body mak­ers Apogee and Spyre, Paragon Ther­a­peu­tics is back with an­oth­er in­flam­ma­to­ry and im­mune dis­ease biotech, and the start­up is im­me­di­ate­ly go­ing to the pub­lic mar­kets.

Waltham, MA-based bi­o­log­ics mak­er Oru­ka Ther­a­peu­tics, fo­cused on chron­ic skin dis­eases like plaque pso­ri­a­sis, has inked a re­verse merg­er agree­ment with a lit­tle-known Col­orado biotech that had at­tempt­ed to break in­to the dif­fi­cult car­dio­vas­cu­lar field of atri­al fib­ril­la­tion, or ir­reg­u­lar and rapid heart rate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.